TALK WITH US. WE'VE BEEN THERE.Let us help you navigate your prostate cancer concerns. PCSANM members are survivors that are here to answer your questions.
2018 Fall Conference
The fall conference was on November 10, 2018. The conference included exhibitors and presenters.
Free Library & Resources
1 in 7 men will get prostate cancer
US Preventative Services Task Force (USPSTF) Revised Guideline on Prostate Cancer Screening
US Preventive Services Task Force "C" Grade for Prostate Cancer Testing
Offer or provide this service for selected patients depending on individual circumstances.
PCSANM's Position on US Preventative Services Task Force Revised Guideline on Prostate Cancer Screening
PCSANM applauds the newly-published guidelines of the USPSTF on prostate cancer screening for being a good start. There is much to be said for the fact that the task force paid attention to dissatisfaction with the prior 2012 guidelines. We also applaud the task force’s emphasis on the importance of shared and informed decision making in testing for prostate cancer.
However, while PCSANM is pleased with the “C” recommendation embodied in the guidelines, there are weaknesses and omissions. Why a “C” but only for men 55-69? Just because the retrospective studies to date have looked more at that age group than others ignores the fact that because prostate cancer is often slow-growing, one doesn’t see the benefits of screening sometimes for more than 10-15 years. Screening early means fewer chances of developing metastatic disease during those years, so why wait until 55 to start testing? We believe that a man’s first, baseline PSA should be around the age of 45, establishing risk and personalizing future follow up. That risk stratification is critical. PSA is just a data point; it is what you do with that information that is important.
Why does the USPSTF (that worries about over treatment if a man is diagnosed) not recommend genomic testing, MRI, liquid biopsies, and other indolent disease that might lead to active surveillance rather than treatment? Why stop testing at age 70 and classify that as a “D” recommendation? Both the American Cancer Society and National Comprehensive Cancer Network talk about testing for men with at least a ten-year life expectancy– that should be the criterion, not an arbitrary age marker. And veterans, especially those who were exposed to Agent Orange, should be included in the “higher risk” population for earlier testing, along with African-American men and men with a positive family history.
PCSANM helps all interested individuals and their families who are involved in coping with this disease.
- Publications and other reading materials on a wide variety of prostate cancer subjects
- Free one-on-one consultations for those diagnosed with prostate cancer and those dealing with the diagnosis of a loved one
- A list of survivors willing to discuss their treatment experience and side effects
- Bi-monthly support meetings including presentations by medical professionals expert in prostate cancer and related topics
- Outreach activities at conferences and health fairs
- Educational presentations to organizations
- Vouchers for free PSA tests for those who have no medical insurance, no primary care physician, or are experiencing troubling symptoms
We offer education, information, and support, but not medical advice.
Upcoming Events & Meetings
Watch this presentation given by Alan W. Shindel, MD, MAS, during the Jackson Hole Seminars on January 30,...read more
Researchers characterize 3 ways in which the gene FOXA1 mutates to trigger prostate...read more
FDA Approves Bayer’s Nubeqa (dardutamide), a New Treatment for Men with Non-Metastatic Castrate-Resistant Prostate Cancer
Read more about the approval of this androgen receptor inhibitor for patients with...read more